IN FOCUS: Solvias
Pharmaceutical Technology
DECEMBER 9, 2022
The move is particularly timely given the significant growth expected in global sales of cell and gene therapies. Beyond our expertise in small molecules, we have built a solid reputation with biopharmaceutical companies for the characterisation and analysis of monoclonal antibodies, therapeutic proteins and biosimilars.
130 
Let's personalize your content